Sweden's Hansa Biopharma Q1 revenue drops 48% amid commercial reorganization in Europe

Hansa Biopharma AB

23/04/2026 06:19

Overview

Sweden biopharma firm's Q1 revenue fell sharply yr/yr amid commercial reorganization impact

Q1 net loss widened as operating expenses rose and revenue declined

Company extended cash runway with USD 30 mln convertible note ahead of potential US launch

Outlook

Hansa Biopharma's imlifidase BLA has a PDUFA target date of Dec. 19, 2026

Company says commercial reorganization expected to support improved performance from Q2 onward

Preparations for a potential U.S. launch are ongoing ahead of possible FDA approval

Result Drivers

COMMERCIAL REORGANIZATION - Co said Q1 revenue was affected by the expected short-term impact of commercial reorganization and related initiatives in Europe

REVENUE VARIABILITY - Co said quarterly revenues remain inherently variable due to structural issues related to organ allocation, with no expected change in the medium term

CASH RUNWAY EXTENDED - USD 30 mln convertible note strengthened financial position ahead of potential US launch

Company press release: ID:nWkr7HbWx3

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
SEK 34.60 mln
Q1 Adjusted EPS
-SEK 1.93
Q1 Net Income
-SEK 196.30 mln
Q1 Cash & Investments
SEK 676.50 mln
Q1 EBIT
-SEK 142.50 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Hansa Biopharma AB is SEK80.00, about 195% above its April 22 closing price of SEK27.12

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)